Table 2.
US Potential Savings of Moving Pediatric Influenza Vaccinations (TIV and LAIV) Before November From the Societal Perspective
| Age Group, ya | No. Currently Vaccinated, millions | Potential Savings From Moving 1000 Vaccinations to Before November
|
Potential Savings From Moving All Vaccinations to Before November
|
||
|---|---|---|---|---|---|
| Costs, $ | QALYs | Costs, $, millions | QALYs | ||
| November | |||||
|
| |||||
| 2–4 | 2.27 | 261–371 | 0.02–0.03 | 0.59–0.84 | 39–57 |
|
| |||||
| 5–9 | 1.41 | 134–183 | 0.02–0.03 | 0.19–0.26 | 24–35 |
|
| |||||
| 10–14 | 1.41 | 132–178 | 0.02–0.02 | 0.19–0.25 | 25–34 |
|
| |||||
| 15–18 | 1.51 | 126–193 | 0.02–0.02 | 0.19–0.29 | 24–36 |
|
| |||||
| December | |||||
|
| |||||
| 2–4 | 0.92 | 656–943 | 0.05–0.07 | 0.60–0.87 | 42–61 |
|
| |||||
| 5–9 | 0.57 | 351–494 | 0.05–0.07 | 0.20–0.28 | 27–38 |
|
| |||||
| 10–14 | 0.57 | 345–474 | 0.05–0.06 | 0.20–0.27 | 26–37 |
|
| |||||
| 15–18 | 0.62 | 347–504 | 0.04–0.07 | 0.21–0.31 | 27–41 |
|
| |||||
| January | |||||
|
| |||||
| 2–4 | 0.47 | 1854–2662 | 0.14–0.18 | 0.87–1.25 | 66–86 |
|
| |||||
| 5–9 | 0.30 | 983–1406 | 0.13–0.19 | 0.29–0.41 | 39–55 |
|
| |||||
| 10–14 | 0.30 | 966–1335 | 0.13–0.18 | 0.28–0.39 | 38–53 |
|
| |||||
| 15–18 | 0.31 | 963–1425 | 0.13–0.19 | 0.30–0.45 | 39–58 |
|
| |||||
| February | |||||
|
| |||||
| 2–4 | 0.25 | 2939–4229 | 0.22–0.29 | 0.74–1.07 | 54–73 |
|
| |||||
| 5–9 | 0.16 | 1532–2184 | 0.21–0.29 | 0.24–0.34 | 32–46 |
|
| |||||
| 10–14 | 0.16 | 1519–2105 | 0.21–0.29 | 0.24–0.33 | 32–45 |
|
| |||||
| 15–18 | 0.17 | 1530–2220 | 0.20–0.29 | 0.26–0.37 | 33–49 |
|
| |||||
| March | |||||
|
| |||||
| 2–4 | 0.08 | 5123–7258 | 0.36–0.50 | 0.43–0.61 | 31–42 |
|
| |||||
| 5–9 | 0.05 | 2634–3694 | 0.35–0.50 | 0.14–0.19 | 18–26 |
|
| |||||
| 10–14 | 0.05 | 2589–3632 | 0.35–0.49 | 0.14–0.19 | 18–26 |
|
| |||||
| 15–18 | 0.06 | 2625–3758 | 0.35–0.49 | 0.15–0.21 | 19–28 |
|
| |||||
| Total | — | — | — | 6.44–9.19 | 653–926 |
LAIV indicates live attenuated influenza vaccine; QALYs, quality-adjusted life-years; TIV, trivalent inactivated virus vaccine.
Percentages of vaccine coverage are 32.0% (2–4 years), 20.8% (5–9 years), 20.8% (10–14 years), and 20.8% (15–18 years), from the Centers for Disease Control and Prevention.23